Harrow (HROW) Tax Provisions (2017 - 2026)

Harrow (HROW) posted quarterly Tax Provisions of $25000.0 for Q1 2026, up 104.86% quarter-over-quarter from -$514000.0 in Q4 2024.

Harrow (HROW) Tax Provisions (2017 - 2026) Analysis & Trends

Harrow's Tax Provisions history runs 5 years deep, the most recent figure standing at $25000.0 for Q1 2026.

In Q1 2026, Tax Provisions changed N/A year-over-year to $25000.0; the TTM figure through Mar 2026 stood at $186000.0 (changed N/A YoY), while the FY2025 annual figure was $3.8 million, up 2242.24% from the prior year.
Tax Provisions for Q1 2026 stood at $25000.0, up from -$514000.0 in the prior quarter.
The five-year high for Tax Provisions was $1.5 million in Q3 2023, with the low at -$535000.0 in Q4 2023.
The 4-year median for Tax Provisions is $22500.0 (2024), against an average of $96200.0.
The sharpest annual moves came in 2023 and 2024: Tax Provisions plunged 137.5% in 2023, then surged 4466.67% in 2024.
Harrow's Tax Provisions stood at $35000.0 in 2022, then tumbled by 1628.57% to -$535000.0 in 2023, then grew by 3.93% to -$514000.0 in 2024, then surged by 104.86% to $25000.0 in 2026.
Business Quant data shows HROW's Tax Provisions at $25000.0 in Q1 2026, -$514000.0 in Q4 2024, and $20000.0 in Q3 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Taxes (Qtr)
1	Haleon	44.07 Bn	43.10 Bn	-	-
2	Teva Pharmaceutical Industries	43.41 Bn	39.75 Bn	2.15 Bn	121.00 Mn
3	Zoetis	31.83 Bn	30.15 Bn	1.05 Bn	-
4	Takeda Pharmaceutical	28.77 Bn	22.97 Bn	5.10 Bn	-310.32 Mn
5	United Therapeutics	22.27 Bn	19.61 Bn	683.80 Mn	39.70 Mn
6	Viatris	18.76 Bn	17.87 Bn	1.46 Bn	54.80 Mn
7	Neurocrine Biosciences	15.65 Bn	15.26 Bn	935.80 Mn	17.80 Mn
8	Elanco Animal Health	11.93 Bn	11.40 Bn	798.00 Mn	2.00 Mn
9	Dr Reddys Laboratories	10.16 Bn	10.00 Bn	-	-
10	Harrow	1.59 Bn	1.51 Bn	50.36 Mn	-

Download Data